Viking Global Investors LP Genmab A/S Transaction History

Viking Global Investors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$30.92 - $44.4 $11.7 Million - $16.8 Million	-377,562 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$33.66 - $40.76 $28,341 - $34,319	-842 Reduced 0.22%	377,562 $15.4 Million
Q3 2020 Nov 16, 2020	SELL	$33.07 - $38.68 $6.5 Million - $7.61 Million	-196,682 Reduced 34.2%	378,404 $13.9 Million
Q2 2020 Aug 07, 2020	SELL	$20.05 - $33.89 $5.33 Million - $9.01 Million	-265,899 Reduced 31.62%	575,086 $19.5 Million
Q1 2020 May 13, 2020	BUY	$17.15 - $25.22 $4.38 Million - $6.45 Million	255,676 Added 43.68%	840,985 $17.8 Million
Q4 2019 Feb 13, 2020	SELL	$18.88 - $24.14 $144,564 - $184,839	-7,657 Reduced 1.29%	585,309 $13.1 Million
Q3 2019 Nov 13, 2019	BUY	$18.0 - $21.38 $10.7 Million - $12.7 Million	592,966 New	592,966 $12 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.